VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Women of child bearing potential must test         │ Women of child bearing potential must test         │     100 │
│ negative on standard pregnancy test (urine or      │ negative on standard pregnancy test (urine or      │         │
│ serum)                                             │ serum)                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients diagnosed severe sepsis / septic shock at │ Patients diagnosed severe sepsis / septic shock at │     100 │
│ admission on Intensive Care Unit who can be        │ admission on Intensive Care Unit who can be        │         │
│ enrolled within 90 min after admission OR patients │ enrolled within 90 min after admission OR patients │         │
│ diagnosed severe sepsis / septic shock during      │ diagnosed severe sepsis / septic shock during      │         │
│ Intensive Care Unit stay who can be enrolled       │ Intensive Care Unit stay who can be enrolled       │         │
│ within 90 min after diagnosis                      │ within 90 min after diagnosis                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients where antibiotic therapy has already been │ Patients where antibiotic therapy has already been │     100 │
│ started (prior to randomization)                   │ started (prior to randomization)                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient who are fluid responsive. Fluid            │ Patient who are fluid responsive. Fluid            │     100 │
│ responsiveness is defined as increase of \> 10% in │ responsiveness is defined as increase of > 10% in  │         │
│ mean arterial pressure (MAP) after passive leg     │ mean arterial pressure (MAP) after passive leg     │         │
│ raising (PLR)                                      │ raising (PLR)                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Signed informed consent by patient, legal          │ Signed informed consent by patient, legal          │     100 │
│ representative or authorized person or deferred    │ representative or authorized person or deferred    │         │
│ consent                                            │ consent                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Administration of HES, dextrane solutions or \>    │ Administration of HES, dextrane solutions or > 500 │     100 │
│ 500 ml of Gelatin solutions within the 24 h prior  │ ml of Gelatin solutions within the 24 h prior to   │         │
│ to randomization                                   │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients for whom the need of pressure infusions   │ Patients for whom the need of pressure infusions   │     100 │
│ are expected                                       │ are expected                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Requirement for renal support (either continuous   │ Requirement for renal support (either continuous   │     100 │
│ or discontinuous techniques, including             │ or discontinuous techniques, including             │         │
│ intermittent haemodialysis, haemofiltration and    │ intermittent haemodialysis, haemofiltration and    │         │
│ haemodiafiltration)                                │ haemodiafiltration)                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients receiving therapeutic heparin medication  │ Patients receiving therapeutic heparin medication  │     100 │
│ due to chronic coagulation disease /               │ due to chronic coagulation disease /               │         │
│ anticoagulation medication (i.e. partial           │ anticoagulation medication (i.e. partial           │         │
│ thromboplastin time \> 60 sec)                     │ thromboplastin time > 60 sec)                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acutely burned patients                            │ Acutely burned patients                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindications according to summary of product  │ Contraindications according to summary of product  │     100 │
│ characteristics of investigational test and        │ characteristics of investigational test and        │         │
│ reference product                                  │ reference product                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Simultaneous participation in another              │ Simultaneous participation in another              │     100 │
│ interventional clinical trial (drugs or medical    │ interventional clinical trial (drugs or medical    │         │
│ devices studies)                                   │ devices studies)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male or female patients ≥ 18 years of age          │ Male or female patients = 18 and = 85 years of age │      88 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Death expected within the next 48 h (moribund      │ Death expected within the next 48 h (moribund      │      99 │
│ patients as defined by ASA ≥ class V)              │ patients as defined by ASA = class V)              │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                               │ CHIA Criteria                                      │   Score │
╞═════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years               │ Male or female patients = 18 and = 85 years of age │      41 │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 85 Years               │ Male or female patients = 18 and = 85 years of age │      43 │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with confirmed acute SARS-CoV-2        │ Patients where antibiotic therapy has already been │      43 │
│ (COVID-19) infection (as available from routine │ started (prior to randomization)                   │         │
│ medical records/ patient chart)                 │                                                    │         │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with body weight ≤ 140 kg              │ Patients with body weight = 55 kg and = 140 kg and │      56 │
│                                                 │ body mass index (BMI) = 18 kg/m2                   │         │
╘═════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒══════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                │ CHIA Criteria                                      │   Score │
╞══════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patients for whom the need of pressure infusions │ Patients whose medical condition does preclude the │      48 │
│ are expected                                     │ PLR manoeuvre                                      │         │
├──────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with body weight ≤ 140 kg               │ Patients with body weight = 55 kg and = 140 kg and │      56 │
│                                                  │ body mass index (BMI) = 18 kg/m2                   │         │
╘══════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 91
Average Levenshtein Ratio of individual lines: 83.7
OverAll Ratio: 87.35
